Palbociclib Capsules

The world's first CDK4/6 targeted inhibitor approved for HR+/HER2-type locally advanced or metastatic breast cancer

Breast cancer is the most common malignant tumor in women, of which HR+/HER2-breast cancer accounts for more than 60%. Palbociclib is the world's first approved CDK4/6 inhibitor, and its emergence opens a new era of endocrine therapy for HR+/HER2-advanced breast cancer. Compared with previous endocrine therapy alone, the combination of Palbociclib significantly extends the survival time of patients.

Indications:

Palbociclib capsules are indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: 

- an aromatase inhibitor as initial endocrine-based therapy; or 

- fulvestrant in patients with disease progression following endocrine therapy. 

Palbociclib capsules are indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.

STRENGTH:

75mg/capsule

100mg/capsule

125mg/capsule